Trametinib Dimethyl Sulfoxide Patent Expiration
Trametinib Dimethyl Sulfoxide is used for treating various cancers, including melanoma, anaplastic thyroid cancer, non-small cell lung cancer, and low-grade glioma, in combination with dabrafenib. It was first introduced by Novartis Pharmaceuticals Corp
Trametinib Dimethyl Sulfoxide Patents
Given below is the list of patents protecting Trametinib Dimethyl Sulfoxide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mekinist | US10869869 | Method of adjuvant cancer treatment | Aug 30, 2033 | Novartis |
| Mekinist |
US10869869 (Pediatric) | Method of adjuvant cancer treatment | Mar 02, 2034 | Novartis |
| Mekinist | US7378423 | Pyrimidine compound and medical use thereof | May 29, 2027 | Novartis |
| Mekinist |
US7378423 (Pediatric) | Pyrimidine compound and medical use thereof | Nov 29, 2027 | Novartis |
| Mekinist | US8580304 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist |
US8580304 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist | US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Oct 15, 2030 | Novartis |
| Mekinist |
US8703781 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Apr 15, 2031 | Novartis |
| Mekinist | US8835443 | Pyrimidine compound and medical use thereof | Jun 10, 2025 | Novartis |
| Mekinist |
US8835443 (Pediatric) | Pyrimidine compound and medical use thereof | Dec 10, 2025 | Novartis |
| Mekinist | US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Oct 15, 2030 | Novartis |
| Mekinist |
US8952018 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Apr 15, 2031 | Novartis |
| Mekinist | US9155706 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist |
US9155706 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist | US9271941 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist |
US9271941 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist | US9399021 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist |
US9399021 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳